This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): XL-880, XL880, GSK1363089, GSK089
Description: XL880 is the third Spectrum Selective Kinase Inhibitor (SSKI) in Exelixis's pipeline. In pre-clinical studies, XL880 demonstrated potent inhibition of the Met and VEGFR2 (KDR) receptor tyrosine kinases (RTKs) which play synergistic roles in promoting tumor growth and angiogenesis. In addition to VEGF and Met, XL880 has potent activity against other RTKs that have been implicated in various forms of cancer including KIT, platelet-derived growth factor (PDGF) receptors, FMS-like tyrosine kinase 3 (FLT3), and Tie-2.
Deal Structure: Pursuant to a product development and commercialization agreement between Exelixis and GlaxoSmithKline (GSK), GSK has the option, after completion of Phase IIa clinical trials, to elect to develop a certain number of compounds in Exelixis' product pipeline (other than the company's cancer compound XL119), which may include XL880, thus potentially triggering milestone payments and royalties from GSK and co-promotion rights by Exelixis.
In August 2007, Exelixis agreed to a request GSK to initiate its review of XL880 before the compound reaches proof-of-concept.
In December 2007, Exelixis announced that GlaxoSmithKline exercised its option to exclusively license XL880 for further development and commercialisation. Under the terms of the collaboration between Exelixis and GSK initiated in October 2002 and amended in January 2005, GSKs selection of XL880 entitles Exelixis to a selection milestone of $35 million and additional payments upon the attainment of specific development and...See full deal structure in Biomedtracker
Partners: GlaxoSmithKline plc
Additional information available to subscribers only: